Form 424B5 - Prospectus [Rule 424(b)(5)]:
SEC Accession No. 0001104659-25-119967
Filing Date
2025-12-10
Accepted
2025-12-10 16:01:19
Documents
6

Document Format Files

Seq Description Document Type Size
1 424B5 tm2531595-4_424b5.htm 424B5 878217
2 GRAPHIC lg_addextherapeutics-4c.jpg GRAPHIC 13106
3 GRAPHIC tb_partneredprog-4clr.jpg GRAPHIC 39406
4 GRAPHIC tb_drugcandi-4clr.jpg GRAPHIC 46076
5 GRAPHIC tb_researchprog-4clr.jpg GRAPHIC 30559
6 GRAPHIC tb_neurosterix-4clr.jpg GRAPHIC 64764
  Complete submission text file 0001104659-25-119967.txt   1147051
Mailing Address CHEMIN DES MINES 9 GENEVA V8 CH-1202
Business Address CHEMIN DES MINES 9 GENEVA V8 CH-1202 01141228841555
Addex Therapeutics Ltd. (Filer) CIK: 0001574232 (see all company filings)

EIN.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: 424B5 | Act: 33 | File No.: 333-291644 | Film No.: 251561913
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)